• LAST PRICE
    3.1000
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-1.2739%)
  • Bid / Lots
    3.0600/ 1
  • Ask / Lots
    3.1900/ 2
  • Open / Previous Close
    3.1100 / 3.1400
  • Day Range
    Low 3.0550
    High 3.1600
  • 52 Week Range
    Low 2.5200
    High 4.8000
  • Volume
    395,135
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.14
TimeVolumeOVID
09:32 ET35773.1
09:33 ET7163.12
09:35 ET5003.13
09:37 ET1003.13
09:39 ET9823.11
09:44 ET2003.09
09:46 ET3003.08
09:48 ET56033.1
09:50 ET51013.13
09:51 ET79953.1244
09:53 ET42893.1224
09:55 ET34123.12
10:02 ET13003.13
10:06 ET17003.13
10:08 ET10003.13
10:09 ET15603.1175
10:11 ET4383.125
10:13 ET20863.125
10:15 ET4043.125
10:18 ET14083.1207
10:20 ET21553.095
10:24 ET5243.11
10:26 ET17003.1
10:27 ET16003.12
10:29 ET9003.12
10:31 ET36003.12
10:33 ET4003.11
10:36 ET24003.1202
10:40 ET2903.115
10:42 ET5003.11
10:44 ET5813.09
10:47 ET7003.1
10:51 ET21023.12
10:56 ET28203.11
10:58 ET22073.12
11:00 ET13143.11
11:02 ET8143.09
11:03 ET5003.09
11:05 ET1003.1
11:07 ET8003.1
11:12 ET24123.09
11:16 ET146793.12
11:20 ET1003.125
11:21 ET3003.13
11:27 ET18003.15
11:32 ET44413.135
11:38 ET13003.12
11:45 ET3003.13
11:52 ET1003.125
11:54 ET72013.11
11:56 ET7633.11
11:57 ET4003.125
11:59 ET25003.11
12:01 ET13003.12
12:03 ET21003.125
12:06 ET12003.13
12:08 ET15003.135
12:10 ET10003.13
12:14 ET11003.1125
12:21 ET6003.11
12:24 ET93853.08
12:26 ET139263.14
12:28 ET4003.12
12:32 ET3003.12
12:35 ET24523.12
12:37 ET27983.11
12:39 ET666843.12
12:48 ET34003.12
12:50 ET8503.12
12:51 ET14533.115
12:53 ET7003.12
12:55 ET12003.125
12:57 ET8003.125
01:00 ET5003.13
01:02 ET5003.125
01:04 ET52923.115
01:06 ET19003.115
01:08 ET8003.12
01:09 ET7003.115
01:11 ET17683.12
01:13 ET78373.11
01:15 ET6003.115
01:18 ET18003.12
01:20 ET11003.11
01:29 ET1003.11
01:31 ET5003.11
01:38 ET1003.11
01:40 ET1003.105
01:42 ET14743.12
01:44 ET7953.12
01:45 ET27003.11
01:47 ET21973.11
01:49 ET1003.11
01:54 ET4263.115
01:58 ET9743.115
02:00 ET2003.115
02:03 ET10003.12
02:07 ET44493.12
02:14 ET3003.12
02:16 ET15003.12
02:20 ET1003.115
02:21 ET1003.115
02:25 ET296043.14
02:27 ET1003.13
02:32 ET20003.105
02:36 ET17003.09
02:38 ET10543.09
02:39 ET3223.09
02:56 ET4003.08
02:57 ET1003.08
02:59 ET1003.075
03:03 ET5743.075
03:08 ET25003.07
03:10 ET4003.07
03:12 ET37813.06
03:14 ET4003.055
03:17 ET11253.065
03:19 ET10003.07
03:21 ET34983.08
03:24 ET6233.08
03:26 ET2003.08
03:28 ET3003.075
03:30 ET9003.07
03:32 ET6293.07
03:33 ET48593.09
03:35 ET5003.09
03:39 ET78053.11
03:42 ET1003.105
03:44 ET3053.11
03:46 ET7003.1
03:50 ET16253.0937
03:51 ET10003.095
03:53 ET79163.11
03:55 ET6153.11
03:57 ET50493.105
04:00 ET290283.1
Data delayed at least 15 minutes.

Jan 3, 2022

6:30AM ET on Monday Jan 03, 2022 by GlobeNewswire
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOVID
Ovid Therapeutics Inc
211.1M
1.7x
---
United StatesEPZM
Epizyme Inc
215.1M
-0.8x
---
United StatesKMPH
KemPharm Inc
228.9M
-1.6x
---
United StatesAMAM
Ambrx Biopharma Inc
195.1M
0.0x
---
United StatesURGN
Urogen Pharma Ltd
170.6M
-1.5x
---
United StatesALPN
Alpine Immune Sciences Inc
245.4M
-4.8x
---
As of 2022-01-22

Company Information

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. The Company's product pipeline includes two late-stage programs and several early-stage programs. The product candidates in its pipeline includes OV935 (soticlestat), OV329, OV882 and OV815. Soticlestat, which is under late-stage program, is for the treatment of dravet syndrome and lennox-gastaut syndrome. OV329, which is under late-stage program, is focused on treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV882, which is under early-stage program, is for the treatment of angelman syndrome and is being developed in collaboration with the University of Connecticut School of Medicine. OV815 is for the treatment of KIF1A Associated Neurological Disorder (KAND) and is being developed in collaboration with Columbia University Irving Medical Center.

Contact Information

Headquarters
1460 Broadway Ste 15044NEW YORK, NY, United States 10036-7329
Phone
646-661-7661
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Jeremy Levin
Chief Business and Financial Officer
Jeffrey Rona
Chief Compliance Officer, General Counsel, Corporate Secretary
Thomas Perone
Chief Commercial Officer
Jason Tardio
Lead Independent Director
Bart Friedman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$211.1M
Revenue (TTM)
$214.1M
Shares Outstanding
68.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.60
EPS
$1.79
Book Value
$0.66
P/E Ratio
1.7x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
1.7x
Operating Margin
60.24%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.